丁丙诺啡用于缓刑犯和假释犯的治疗。
Buprenorphine Treatment for Probationers and Parolees.
作者信息
Gordon Michael S, Kinlock Timothy W, Schwartz Robert P, Couvillion Kathryn A, Sudec Laura J, O'Grady Kevin E, Vocci Frank J, Shabazz Hamin
机构信息
a Department of Psychology , Friends Research Institute , Baltimore , Maryland , USA.
出版信息
Subst Abus. 2015;36(2):217-25. doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4.
Abstract
BACKGROUND
Pharmacotherapy studies involving buprenorphine have rarely been conducted with U.S. community corrections populations. This is one of the first reports of buprenorphine treatment outcomes of adult opioid-dependent probationers and parolees.
METHODS
This longitudinal study examined the 3-month treatment outcomes for a sample of probation and parole clients (N = 64) who received community-based buprenorphine treatment.
RESULTS
Approximately two thirds of the sample (67%) were still in treatment at 3 months post baseline. Furthermore, there was a significant decline in the number of self-reported heroin use days and crime days from baseline to 3 months post baseline. Although there was not a significant reduction in reincarcerations, there was no evidence that they had increased.
CONCLUSIONS
Given that buprenorphine is approved by the Food and Drug Administration (FDA) as a safe, effective treatment for opioid use disorders, individuals on parole or probation should have the opportunity to benefit from it through community-based programs.
摘要
背景
涉及丁丙诺啡的药物治疗研究很少在美国社区矫正人群中进行。这是关于成年阿片类药物依赖缓刑犯和假释犯丁丙诺啡治疗结果的首批报告之一。
方法
这项纵向研究考察了接受社区丁丙诺啡治疗的缓刑和假释客户样本（N = 64）的3个月治疗结果。
结果
大约三分之二的样本（67%）在基线后3个月仍在接受治疗。此外，从基线到基线后3个月，自我报告的海洛因使用天数和犯罪天数显著下降。虽然再次入狱的人数没有显著减少，但也没有证据表明其有所增加。
结论
鉴于丁丙诺啡已被美国食品药品监督管理局（FDA）批准为阿片类药物使用障碍的安全、有效治疗方法，假释或缓刑人员应有机会通过社区项目从中受益。
相似文献
1
Buprenorphine Treatment for Probationers and Parolees.丁丙诺啡用于缓刑犯和假释犯的治疗。
Subst Abus. 2015;36(2):217-25. doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4.
2
A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.美沙酮用于缓刑犯和假释犯的随机对照试验：弥合治疗缺口。
Contemp Clin Trials. 2019 Apr;79:21-27. doi: 10.1016/j.cct.2019.02.009. Epub 2019 Feb 20.
3
Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.按假释和缓刑状态划分的非裔美国丁丙诺啡患者的治疗结果
J Drug Issues. 2014 Jan;44(1):69-82. doi: 10.1177/0022042613491106.
4
A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.澳大利亚新南威尔士州美沙酮和丁丙诺啡维持治疗阿片类药物依赖的纵向比较。
Addiction. 2015 Apr;110(4):646-55. doi: 10.1111/add.12834.
5
Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment.美沙酮患者在缓刑/假释期间的治疗结果得到改善，无论早期治疗中是否接受咨询。
J Addict Med. 2013 Mar-Apr;7(2):133-8. doi: 10.1097/ADM.0b013e318284a0c1.
6
Pharmacotherapy for opioid addiction in community corrections.社区矫正中的阿片类药物成瘾的药物治疗。
Int Rev Psychiatry. 2018 Oct;30(5):117-135. doi: 10.1080/09540261.2018.1524373. Epub 2018 Dec 6.
7
Opioid agonist treatment for pharmaceutical opioid dependent people.用于药物性阿片类物质依赖者的阿片类激动剂治疗
Cochrane Database Syst Rev. 2016 May 9(5):CD011117. doi: 10.1002/14651858.CD011117.pub2.
8
Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.芬太尼使用对丁丙诺啡治疗保留和阿片类药物戒断的影响。
J Addict Med. 2019 Jul/Aug;13(4):253-257. doi: 10.1097/ADM.0000000000000486.
9
Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.海洛因依赖患者阿片类药物维持治疗的六年结果：一项全国代表性样本的自然主义研究结果
Eur Addict Res. 2017;23(2):97-105. doi: 10.1159/000468518. Epub 2017 Apr 5.
10
Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.基于门诊的丁丙诺啡治疗：确定促进阿片类药物依赖患者留存的因素。
J Addict Nurs. 2020 Jan/Mar;31(1):23-29. doi: 10.1097/JAN.0000000000000320.
引用本文的文献
1
Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners.刑事法律系统背景下阿片类物质使用障碍的联动促进：研究人员、临床医生和法律从业者入门指南
Health Justice. 2024 Aug 29;12(1):36. doi: 10.1186/s40352-024-00291-8.
2
Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.纳入监狱/看守所的阿片类药物使用障碍治疗药物的预算影响工具。
J Subst Use Addict Treat. 2023 Mar;146:208943. doi: 10.1016/j.josat.2022.208943. Epub 2023 Jan 26.
3
Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study.一项针对阿片类物质使用障碍患者的计算机化行为疗法与康复指导相结合的综合干预随机试点试验的原理、设计与方法：OVERCOME研究
Contemp Clin Trials Commun. 2022 May 5;28:100918. doi: 10.1016/j.conctc.2022.100918. eCollection 2022 Aug.
4
Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.接受丁丙诺啡治疗的医疗补助受种者的治疗质量在社会人口统计学方面的差异。
Subst Abus. 2022 Dec;43(1):1057-1071. doi: 10.1080/08897077.2022.2060424.
5
Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.监禁是否会影响患者治疗阿片类药物使用障碍的目标？对监狱中丁丙诺啡治疗的定性研究。
Drug Alcohol Depend. 2021 May 1;222:108529. doi: 10.1016/j.drugalcdep.2021.108529. Epub 2021 Mar 18.
6
Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol.利用实施干预和同伴康复支持来改善社区监管中的阿片类药物治疗效果：方案。
J Subst Abuse Treat. 2021 Sep;128:108364. doi: 10.1016/j.jsat.2021.108364. Epub 2021 Mar 12.
7
Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System.在刑事司法系统中治疗阿片类药物使用障碍和相关传染病。
Infect Dis Clin North Am. 2020 Sep;34(3):585-603. doi: 10.1016/j.idc.2020.06.012.
8
Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.在有阿片类药物使用障碍的在押囚犯中使用缓释纳曲酮的健康和经济结果（HOPPER）：两项随机有效性试验评估的方案。
Addict Sci Clin Pract. 2020 Apr 22;15(1):15. doi: 10.1186/s13722-020-00188-5.
9
Pharmacotherapy for opioid addiction in community corrections.社区矫正中的阿片类药物成瘾的药物治疗。
Int Rev Psychiatry. 2018 Oct;30(5):117-135. doi: 10.1080/09540261.2018.1524373. Epub 2018 Dec 6.
10
Italian psychiatry.意大利精神病学。
Int Rev Psychiatry. 2018 Apr;30(2):117. doi: 10.1080/09540261.2018.1435761.
本文引用的文献
1
A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol.一项针对患有物质使用障碍的罪犯的组织联系干预措施的整群随机试验：研究方案。
Health Justice. 2013 Dec 19;1(6). doi: 10.1186/2194-7899-1-6.
2
Gender Differences Among Prisoners With Pre-Incarceration Heroin Dependence Participating in a Randomized Clinical Trial of Buprenorphine Treatment.参与丁丙诺啡治疗随机临床试验的入狱前有海洛因依赖的囚犯中的性别差异
J Offender Rehabil. 2013 Jan 1;52(5):376-391. doi: 10.1080/10509674.2013.801386.
3
Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment.美沙酮患者在缓刑/假释期间的治疗结果得到改善，无论早期治疗中是否接受咨询。
J Addict Med. 2013 Mar-Apr;7(2):133-8. doi: 10.1097/ADM.0b013e318284a0c1.
4
A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.一项针对非裔美国人的密集门诊（IOP）与标准门诊（OP）丁丙诺啡治疗的随机试验。
Drug Alcohol Depend. 2013 Mar 1;128(3):222-9. doi: 10.1016/j.drugalcdep.2012.08.027. Epub 2012 Sep 20.
5
The first 90 days following release from jail: findings from the Recovery Management Checkups for Women Offenders (RMCWO) experiment.出狱后 90 天内：女性罪犯康复管理检查（RMCWO）实验的结果。
Drug Alcohol Depend. 2012 Sep 1;125(1-2):110-8. doi: 10.1016/j.drugalcdep.2012.03.025. Epub 2012 Apr 27.
6
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.一项多中心试点研究：使用缓释型纳曲酮注射剂治疗曾有阿片类药物依赖史的假释犯和缓刑犯。
Subst Abus. 2012;33(1):48-59. doi: 10.1080/08897077.2011.609438.
7
Buprenorphine-naloxone maintenance following release from jail.美沙酮-纳洛酮维持治疗在出狱后的应用。
Subst Abus. 2012;33(1):40-7. doi: 10.1080/08897077.2011.620475.
8
Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.刑事司法机构中与刑事司法-药物滥用治疗研究（CJ-DATS）相关的药物辅助治疗：可及性、障碍和意图。
Subst Abus. 2012;33(1):9-18. doi: 10.1080/08897077.2011.611460.
9
Medication-assisted treatment research with criminal justice populations: challenges of implementation.药物辅助治疗与刑事司法人群的研究：实施的挑战。
Behav Sci Law. 2011 Nov-Dec;29(6):829-45. doi: 10.1002/bsl.1015.
10
Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system.一项在刑事司法系统中针对阿片类药物依赖女性的丁丙诺啡随机对照试验的初步结果。
Drug Alcohol Depend. 2011 Dec 15;119(3):172-8. doi: 10.1016/j.drugalcdep.2011.06.021. Epub 2011 Jul 23.
Zotero 插件